STF Management LP Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM)

STF Management LP lowered its position in shares of DexCom, Inc. (NASDAQ:DXCMFree Report) by 9.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,591 shares of the medical device company’s stock after selling 600 shares during the period. STF Management LP’s holdings in DexCom were worth $375,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom in the 2nd quarter worth about $25,000. Sachetta LLC lifted its position in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the period. Crewe Advisors LLC purchased a new stake in shares of DexCom in the 1st quarter worth about $29,000. Riverview Trust Co lifted its position in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. Finally, DT Investment Partners LLC lifted its position in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

DXCM opened at $74.48 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market cap of $29.09 billion, a price-to-earnings ratio of 44.60, a PEG ratio of 2.30 and a beta of 1.17. The company’s 50 day moving average is $70.54 and its 200 day moving average is $90.23. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Oppenheimer decreased their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. JPMorgan Chase & Co. increased their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Leerink Partners decreased their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Barclays decreased their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

Check Out Our Latest Report on DXCM

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

See Also

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.